Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT ID: NCT05563220
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
435 participants
INTERVENTIONAL
2023-01-24
2028-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
NCT01281163
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
NCT00559507
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
NCT03286842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
The treatment arms will be:
* Arm A: 50 participants: elacestrant with alpelisib;
* Arm B: 50 participants: elacestrant with everolimus;
* Arm C: 60 participants (30 participants in each combination): elacestrant with either abemaciclib or ribociclib;
* Arm D: 90 participants (30 participants in each combination): elacestrant with either palbociclib, abemaciclib, or ribociclib;
* Arm E: 60 participants: elacestrant with capivasertib
Phase 1b will have a total of 125 participants, while Phase 2 will have 310 participants for all treatment arm combinations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1b Arm A: elacestrant with alpelisib
Elacestrant Dihydrochloride 300 milligrams (mg) or 400 mg + Alpelisib 150 mg to 250 mg
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Alpelisib
Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
Phase 1b Arm B: elacestrant with everolimus
Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Everolimus
Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
Phase 1b Arm C: elacestrant with abemaciclib or ribociclib:
Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg
The RP2D for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Ribociclib
Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Abemaciclib
Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i)
Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg or the RP2D for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)
Elacestrant 86 mg, 172 mg, 258 mg + Ribociclib 400 mg or possibly 600 mg
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Ribociclib
Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Palbociclib
Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Abemaciclib
Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Phase 1b Arm E:
Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Capivasertib
Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elacestrant
Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Alpelisib
Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
Everolimus
Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
Ribociclib
Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Palbociclib
Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
Capivasertib
Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
Abemaciclib
Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Women or men aged ≥18 years (or the minimum age of consent in accordance with the local law), at the time of informed consent signature. Female participants may be of any menopausal status.
* Postmenopausal status is defined as follows or in accordance with local regulations:
1. Age ≥60 years or
2. Age \<60 years and amenorrhea for 12 or more months (without an alternative cause) and follicle-stimulating hormone value and an estradiol level within the postmenopausal range per local laboratory reference or
3. Documentation of bilateral oophorectomy, at least 1 month before first dose of trial therapy.
* Premenopausal and perimenopausal women (who do not fit postmenopausal criteria) and men must be receiving a luteinizing hormone-releasing hormone (LHRH) agonist and must be initiated at least 3 weeks (4 depending on local label) before the start of trial therapy and are planning to continue LHRH agonist treatment during the study treatment.
3. Histopathological or cytological confirmed ER+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology/College of American Pathologists guidelines. Note: In the context of this trial, ER status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with or without progesterone positivity.
4. Documented radiological disease progression during or after the most recent therapy.
5. At least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor lesions previously irradiated or subjected to any locoregional treatment will only be considered measurable if there is clear, documented progression at the treated site. For participants with bone only disease, lesions: must be lytic or mixed (lytic + blastic / sclerotic), confirmed and accurately assessed by computed tomography or magnetic resonance imaging, and must have an identifiable soft tissue component meeting the definition of measurability per RECIST v1.1. Note: participants with blastic / sclerotic bone lesions only are not eligible.
6. Eastern Cooperative Oncology Group performance status of 0 or 1.
7. Participant has adequate bone marrow and organ function, as defined by the following laboratory values:
1. Absolute neutrophil count ≥1.5 × 10\^9/liter (L)
2. Platelets ≥100 × 10\^9/L
3. Hemoglobin ≥9.0 grams/deciliter (g/dL)
4. Creatinine is ≤ 1.5 x upper limit of normal (ULN) or if creatinine is \> 1.5 x ULN, then creatinine clearance must be ≥50 milliliters/minute based on the Cockcroft-Gault formula. Note: C-G formula:
* Creatinine clearance (male) = (\[140-age in years\] × weight in kilograms \[kg\])/ (\[serum creatinine in milligrams/deciliter (mg/dL)\] × 72)
* Creatinine clearance (female) = (0.85 × \[140-age in years\] × weight in kg)/ (\[serum creatinine in mg/dL\] × 72)
f. Serum albumin ≥3.0 g/dL (≥30 g/L)
g. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN. If the participant has liver metastases, ALT and AST ≤ 5 × ULN
h. Total serum bilirubin \<1.5 × ULN except for participants with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.
Additional Criteria for the Alpelisib Combination (Phase 1b and Arm A): In general, the prescription information of the respective combination drug should be consulted for instructions/restrictions with respect to interactions with concomitant medications.
1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation by local laboratory assessment.
2. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a cyclin-dependent kinase targeting enzymes CDK4 and CDK6 (CDK4/6) inhibitor.
Additional Criteria for the Everolimus Combination (Phase 1b and Arm B), the Abemaciclib Combination (Arm C), the Ribociclib Combination (Phase 1b and Arm C), and the Palbociclib Combination (Phase 1b): One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.
Additional Criteria for the Palbociclib Combination (Arm D), the Abemaciclib Combination (Arm D), and the Ribociclib Combination (Arm D): One or up to two prior hormonal therapies in the advanced or metastatic setting.
Additional Criteria for Capivasertib Combination (Phase 1b and Arm E): Recruitment in this combination will occur only in countries where capivasertib is locally approved and available.
1. PIK3CA/AKT1/PTEN-alteration as detected by an FDA and/or locally approved test (local result).
2. One or up to two prior hormonal therapies in the advanced or metastatic setting or participants who have radiological evidence of breast cancer recurrence or progression within 12 months from the end of adjuvant treatment with endocrine therapy, as these participants are considered as first line relapsed participants. Prior CDK4/6i treatment is allowed but not required.
Exclusion Criteria
2. Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%.
3. Prior chemotherapy or elacestrant in the advanced/metastatic setting.
4. Participants with known germline BRCA mutation without prior treatment with a PARP inhibitor before study entry.
5. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders, or investigational alike agents such as selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, complete estrogen receptor antagonists, and proteolysis-targeting chimeras, in the metastatic setting. Prior treatment with fulvestrant is not exclusionary, except for Arm E, as it is an approved medication.
6. Participant has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy. Other malignancies with low risk of recurrence may be considered eligible with Sponsor approval.
7. Uncontrolled significant active infections.
* Participants with hepatitis B virus and/or hepatitis C virus infection must have undetectable viral load during screening.
* Participants known to be human immunodeficiency virus+ are allowed if they have undetectable viral load at baseline.
8. Documented pneumonitis/interstitial lung disease prior to Cycle 1 Day 1.
9. Major surgery within 28 days before starting trial therapy.
10. Inability to take oral medications, refractory or chronic nausea, gastrointestinal conditions (including significant gastric or bowel resection), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that impact the absorption of the study drug.
11. Known intolerance to elacestrant or any of its excipients.
12. Pregnant and breast-feeding women are excluded from the study. In addition, women of childbearing potential are excluded who:
* Within 28 days before starting trial therapy, did not use a highly effective method of contraception.
* Do not agree to use a highly effective method of contraception (Appendix F) or abstain from heterosexual intercourse throughout the entire study period and for 120 days after trial therapy discontinuation.
13. Men or women who do not agree to abstain from donating sperm or ova, or to use a highly effective method of contraception, 28 days prior, during the course of the treatment period and for 120 days after the last dose of study treatment.
14. Participant is currently receiving or received any of the following medications prior to first dose of trial therapy:
• Anti-cancer therapy within 14 days (28 days for anticancer antibody based treatment) or 5 half-lives, whichever is shorter.
Please note: Toxicity from prior therapy must be resolved to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 Grade ≤1, except alopecia and peripheral sensory neuropathy (Grade ≤2).
* Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (refer to https://drug-interactions.medicine.iu.edu/maintable.aspx or https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers).
* Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng.
* Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to starting trial therapy.
15. Evidence of ongoing alcohol or drug abuse as assessed by the investigator.
16. Any severe medical or psychiatric condition that, in the Investigator's opinion, would preclude the participant's participation in a clinical study.
Additional Criteria for the Alpelisib Combination (Phase 1b and Arm A):
1. Prior therapy with alpelisib or any other phosphoinositide 3-kinase (PI3K) inhibitor.
2. Type 1 diabetes or uncontrolled type 2 diabetes (fasting plasma glucose level of \>140 mg/dL \[7.7 millimole (mmol)/L\], or glycosylated hemoglobin \[HbA1c\] level of \>6.4%).
3. Known intolerance to alpelisib or any of its excipients.
4. Participant is currently receiving or received drugs known to be a breast cancer resistant protein inhibitor (for example, curcumin, cyclosporine A, eltrombopag, febuxostat, fostamatinib, rolapitant, teriflunomide) within 14 days or 5 half-lives, whichever is shorter, prior to first dose of trial therapy (refer to Table 5.2 of https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers).
5. Participant has ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates or denosumab
Additional Criteria for the Everolimus Combination (Phase 1b and Arm B):
1. Prior therapy with everolimus.
2. Known intolerance to everolimus or any of its excipients.
Additional Criteria for the Abemaciclib Combination (Arm C):
1. Prior therapy with abemaciclib in the advanced or metastatic setting. Adjuvant therapy with abemaciclib is also exclusionary.
2. Known intolerance to abemaciclib or any of its excipients.
3. History of deep vein thrombosis or pulmonary embolism (unless on anticoagulation), cerebrovascular accident, or myocardial infarction, in the past 6 months. Participants on anticoagulation should have been on a stable dose for at least 3 months prior to enrollment.
Additional Criteria for the Ribociclib Combination (Phase 1b and Arm C):
1. Prior therapy with ribociclib in the advanced or metastatic setting. Prior adjuvant therapy with ribociclib is also exclusionary.
2. Known intolerance to ribociclib or any of its excipients.
3. QTcF interval corrected by Fridericia formula (QTcF) values ≥450 milliseconds (msec).
4. Participants who already have or who are at significant risk of developing QTc prolongation, including participants with:
* Long QT syndrome
* Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
* Electrolyte abnormalities (K+, Ca++, Phos, Mg++) ≥Grade 1
5. Participant is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.
Additional Criteria for the Palbociclib Combination (Phase 1b):
1. Prior therapy with palbociclib in the advanced or metastatic setting.
2. Known intolerance to palbociclib or any of its excipients
Additional Criteria for the Palbociclib Combination (Arm D):
1. Prior therapy with a CDK4/6i in the metastatic setting.
2. Known intolerance to palbociclib or any of its excipients.
Additional Criteria for the Abemaciclib Combination (Arm D):
1. Prior therapy with any CDK4/6i.
2. Known intolerance to abemaciclib or any of its excipients.
Additional Criteria for Ribociclib Combination (Arm D):
1. Prior therapy with a CDK4/6i in the advanced or metastatic setting.
2. Known intolerance to ribociclib or any of its excipients.
3. QTcF values ≥450 msec.
4. Participants who already have or who are at significant risk of developing QTc prolongation, including participants with:
* Long QT syndrome
* Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
* Electrolyte abnormalities (K+, Ca++, Phos, Mg++) ≥Grade 1
5. Participant is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.
Additional Criteria for Capivasertib Combination (Phase 1b and Arm E): Recruitment in this combination will occur only in countries where capivasertib is locally approved and available.
1. Prior treatment with any of the following: AKT, PI3K and mammalian target of rapamycin inhibitors and, for Arm E, fulvestrant.
2. Known intolerance to capivasertib or any of its excipients.
3. QTcF values ≥470 msec or factors that increase the risk of corrected QT interval (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval.
4. Clinically significant abnormalities of glucose metabolism as defined by any of the following: Participants with diabetes mellitus type 1; participants with diabetes mellitus type 2 requiring insulin treatment or participants with HbA1c level of \>8.0% (63.9 mmol/mol).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stemline Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dothan Hematology and Oncology
Dothan, Alabama, United States
Mayo Clinic - Arizona
Phoenix, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
OPN Healthcare (Arcadia Location)
Arcadia, California, United States
City of Hope National Medical Center
Duarte, California, United States
Glendale Adventist
Glendale, California, United States
OPN Healthcare (Los Alamitos Location)
Los Alamitos, California, United States
Cedars Sinai
Los Angeles, California, United States
UCLA UCLA Hem/Onc - Clinical Research Unit
Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
TOI Clinical Research
Whittier, California, United States
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States
Yale School Of Medicine - Smilow Cancer Hospital - Breast Center
New Haven, Connecticut, United States
George Washington Cancer Center
Washington D.C., District of Columbia, United States
Advent Health (Florida Hospital) - Altamonte Springs
Altamonte Springs, Florida, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Ocala Oncology
Ocala, Florida, United States
Northside Hospital Atlanta Cancer Care
Cumming, Georgia, United States
Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital
Chicago, Illinois, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
MD Alliance for Multispecialty Research, LLC
Merriam, Kansas, United States
New England Cancer Specialists
Scarborough, Maine, United States
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Minnesota Oncology Hematology
Minneapolis, Minnesota, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Astera Cancer Care
East Brunswick, New Jersey, United States
Summit Medical Group
Florham Park, New Jersey, United States
Cooperman Barnabas Medical Center
New Brunswick, New Jersey, United States
NYU Langone Health
New York, New York, United States
New York Cancer and Blood Specialists
Port Jefferson Station, New York, United States
W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island
Providence, Rhode Island, United States
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
MD Anderson Cancer Center Texas
Houston, Texas, United States
UT Health San Antonio
San Antonio, Texas, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Cancer Care Northwest
Spokane Valley, Washington, United States
Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC
Tacoma, Washington, United States
University of WI - Carbone Cancer Center (Phase II only)
Madison, Wisconsin, United States
Centro Medico Austral
Buenos Aires, , Argentina
Hospital Britanico De Buenos Aires
Buenos Aires, , Argentina
Cemaic - Centro De Especialidades Medicas Ambulatorias E Investigacion Clinica
Córdoba, , Argentina
Centro Oncologico Riojano Integral (Cori)
La Rioja, , Argentina
Macquarie University
Sydney, , Australia
Institut Jules Bordet
Anderlecht, , Belgium
Grand Hôpital de Charleroi - Site Notre Dame
Charleroi, , Belgium
Universitaire Ziekenhuizen (Uz) Leuven - Campus Gasthuisberg - Multidisciplinair Borstcentrum (Multidisciplinary Breast Center) (Mbc)
Leuven, , Belgium
Algemeen Ziekenhuis Nikolaas; VITAZ; Oncologie Klinisch Studiecentrum
Sint-Niklaas, , Belgium
ACCG - Hospital Araujo Jorge
Goiânia, , Brazil
Clinica Neoplasias Litoral
Itajaí, , Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, , Brazil
Centro Gaucho Integrado de Oncologia; Hematologia; Ensino e Pesquisa - Hospital Mae de Deus/AESC
Porto Alegre, , Brazil
Hospital Sirio-Libanes (HSL) - Centro De Oncologia - Sao Paulo
São Paulo, , Brazil
Nemocnice Horovice Hospital
Hořovice, , Czechia
Fakultni Nemocnice Olomouc
Olomouc, , Czechia
Centre Hospitalier Lyon SUD- HCL
Lyon, , France
Centre de Cancérologie du Grand Montpellier
Montpellier, , France
Centre de Cancérologie du Grand Montpellier
Rouen, , France
Centre Hospitalier Universitaire (Chu) De Toulouse - Institut Universitaire Du Cancer De Toulouse-Oncopole (Iuct-Oncopole) (Institut Claudius Regaud)
Toulouse, , France
Institut Gustave-Roussy-Umr 981
Villejuif, , France
Universitaetsklinikum Mannheim
Mannheim, Baden-Wurttemberg, Germany
Technischen Universitaet Muenchen (TUM), Klinikum Rechts der Isar
Munich, Bavaria, Germany
Universitatskinikum Carl Gustav Carus Dresden
Dresden, Saxony, Germany
Marienhospital Bottrop
Bottrop, , Germany
Universitatskinikum Carl Gustav Carus Dresden
Dresden, , Germany
Kliniken Essen-Mitte (KEM)
Essen, , Germany
Gesundheit Nordhessen Klinikum Kassel
Kassel, , Germany
Universitaetsklinikum Tuebingen
Tübingen, , Germany
Semmelweis Egyetem Klinikai Kozpont - Onkologiai Intezet
Budapest, , Hungary
Orszagos Onkologiai Intezet
Budapest, , Hungary
Samson Assuta Ashdod University Hospital - The Institute of Oncology
Ashdod, , Israel
Rambam Heath
Haifa, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Davidoff Rabin Medical Center
Petah Tikva, , Israel
Sheba Medical Center; Center Israel
Ramat Gan, , Israel
ASST degli Spedali Civili di Brescia
Brescia, , Italy
Azienda Ospedaliera "Istituti Ospitalieri" Di Cremona
Cremona, , Italy
Istituto Europeo di Oncologia (IEO)
Milan, , Italy
Istituto Nazionale Tumori "Fondazione PASCALE"
Napoli, , Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, , Italy
Ospedale Infermi di Rimini - Azienda Unita Sanitaria Locale Della Romagna
Rimini, , Italy
Centre Hospitalier De L'Ardenne
Libramont, , Luxembourg
Klinika Onkologii; Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
Warsaw, Masovian Voivodeship, Poland
Przychodnia Lekarska "Komed" Roman Karaszewski
Konin, , Poland
Instytut Centrum Zdrowia Matki Polki
Lodz, , Poland
Med-Polonia Sp. Z o.o.
Poznan, , Poland
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Asan Medical Center
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
The Catholic University of Korea - Seoul St. Mary's Hospital
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Complejo Hospitalario Universitario A Coruna
A Coruña, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Clinic Barcelona
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
IOB Madrd Institute of Oncology Hospital Beata Maria Ana de Jesus
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Virgen de la Victoria
Málaga, , Spain
NEXT Madrid
Pozuelo de Alarcón, , Spain
Fundacion Instituto Valeciano De Oncologia
Valencia, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Hospital Arnau De Vilanova
Valencia, , Spain
Abdurrahman Yurtaslan Oncology Hospital
Ankara, , Turkey (Türkiye)
Ankara Bilkent City Hospital, Bilkent Campus, Universiteler Mh. (old: Ankara Yildirim Beyazit Universitesi)
Ankara, , Turkey (Türkiye)
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, , United Kingdom
Liverpool Hospital
Liverpool, , United Kingdom
North Middlesex University Hospital
London, , United Kingdom
Sarah Cannon Research Institute UK; Ltd
London, , United Kingdom
University College London Hospitals NHS Foundation Trust; The London Clinic - Main Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STML-ELA-0222
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.